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Abstract
The glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have become
important options for the management of patients with type 2 diabetes mellitus. While the GLP-1R agonists and
DPP-4 inhibitors act on the incretin system to regulate glucose homeostasis, there are important clinical differences
among the five agents currently available in the U.S. For example, the GLP-1R agonists require subcutaneous
administration, produce pharmacological levels of GLP-1 activity, promote weight loss, have a more robust glucose-
lowering effect, and have a higher incidence of adverse gastrointestinal effects. In contrast, the DPP-4 inhibitors are
taken orally, increase the half-life of endogenous GLP-1, are weight neutral, and are more commonly associated
with nasopharyngitis. Differences in efficacy, safety, tolerability, and cost among the incretin-based therapies are
important to consider in the primary care management of patients with type 2 diabetes mellitus.
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Introduction
Treating patients with type 2 diabetes mellitus (T2DM)
can be very challenging. Fortunately, new treatment
options for T2DM, such as incretin-based agents, provide
new opportunities to bring the disease under control,
and perhaps slow its progression. More recently, focus
has been placed on ‘treating to target’ glucose approaches
rather than waiting for progressive glucose failure. The
goal of the treat-to-target approach is to achieve safe glu-
cose targets for each individual with a combination of
early lifestyle and pharmacologic therapies. As such, it is
important to work with each patient to develop and initi-
ate a lifestyle and pharmacologic treatment plan at the
time of diagnosis of T2DM to achieve the glycemic tar-
get–generally an A1C < 7.0% [1], within 3 to 6 months.
The second and very important part of the treat-to-target
approach is to modify treatment as needed to maintain
the A1C at the target level [2]. Modifying treatment is,
however, often challenging because of hypoglycemia,
weight gain, intolerable adverse events, even access to
and affordability of newer agents, as well as clinical iner-
tia. These and other glycemic and non-glycemic factors
were considered by the American Diabetes Association/
European Society for the Study of Diabetes (ADA/EASD)
[2] and by the American Association of Clinical Endocri-
nologists/American College of Endocrinology (AACE/
ACE) [3] when developing their 2009 guideline recom-
mendations. Both groups concluded that, based upon
their unique physiologic activity, efficacy, nonglycemic
benefits, and safety profiles, agents which act on the
incretin system–the glucagon-like peptide-1 (GLP-1R)
agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors–
are important options for the management of patients
with T2DM. An agent in each class has now been FDA-
approved since 2005 and 2006. (Table 1)
The AACE/ACE guidelines, for example, state that the
GLP-1R agonists and DPP-4 inhibitors are options as
monotherapy for patients with an A1C of 6.5% to 7.5%,
as well as in combination with other glucose-lowering
agents for patients with an A1C > 7.5% (Figure 1). In this
latter situation, the GLP-1R agonists are given a higher
priority than the DPP-4 inhibitors because of the greater
effect of the GLP-1R agonists in reducing postprandial
glucose excursions and their potential for inducing sub-
stantial weight loss. The ADA/EASD recommendations
take a different approach recommending the GLP-1R Correspondence: mcobble@canyonsmedical.com
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any medium, provided the original work is properly cited.agonists (and thiazolidinediones) as less-validated alter-
natives to insulin or sulfonylurea as add-on therapy to
lifestyle management and metformin (Figure 2). The
DPP-4 inhibitors are appropriate for selected but unspe-
cified patients according to the ADA/EASD recommen-
dations, which were published in early 2009.
Physiologic Actions
The multifactorial nature of the pathophysiology
ofT2DM presents several options for treatment, some of
which are not addressed by standard glucose-lowering
therapies. Standard glucose-lowering therapies generally
improve insulin sensitivity, stimulate insulin secretion,
and/or decrease hepatic gluco s ep r o d u c t i o n .T h ei n c r e -
tin system exerts somewhat unique actions upon glucose
homeostasis. In fact, the incretin system may be respon-
sible for up to 70% of insulin secretion in response to
oral glucose or a meal in healthy individuals [4].
Of the two principal incretin hormones, GLP-1 plays a
more important role in T2DM since the insulinotropic
action of glucose-dependent insulinotropic polypeptide
(GIP) is essentially lost in persons with T2DM, while
the insulinotropic activity of GLP-1 following adminis-
tration of pharmacological doses of GLP-1 is preserved
[5].
Extensive preclinical investigations with GLP-1 and
subsequent clinical investigations with the GLP-1R
agonists and DPP-4 inhibitors in humans, including
patients with T2DM, have been undertaken to deter-
mine the actions of each of these agents in regulating
glucose. As expected from studies investigating the
actions resulting from administration of GLP-1, stimula-
tion of the GLP-1 receptor directly with a GLP-1R ago-
nist or indirectly with a DPP-4 inhibitor (by inhibiting
enzymatic degradation of endogenous GLP-1) serves to
increase insulin secretion in a glucose-dependent man-
ner through direct activation of pancreatic islet b-cells
[6-10] and to inhibit glucagon secretion in a glucose-
dependent manner (ie., only during hyperglycemia)
through direct activation of pancreatic islet a-cells
[6,8,9,11-14]. Furthermore, administration of GLP-1 or a
GLP-1R agonist (but not a DPP-4 inhibitor) has been
shown to slow gastric emptying [8,15] and to promote
satiety [8,16,17], which leads to weight loss, although
neither of these effects is required for the glucose-lower-
ing benefits of the GLP-1R agonists. This difference is
thought to be due to the 60 pmol/L pharmacologic level
of GLP-1 activity achieved with administration of a
GLP-1R agonist [18], which is associated with nausea,
compared to the 10 pmol/L physiologic level of endo-
genous GLP-1 activity achieved from administration of a
DPP-4 inhibitor [19].
In addition, exposure to GLP-1 in cell culture [20] or
administration of GLP-1 in rodents [21] has been found
Table 1 Comparison of GLP-1R agonists and DPP-4 inhibitors.
GLP-1R Agonists DPP-4 Inhibitors
Agents currently available in U.S. with dosing information (normal renal function)[31-35] ￿ Exenatide 5-10
mcg SC BID
￿ Liraglutide 1.2-1.8
mg QD
￿ Sitagliptin 100 mg
PO QD
￿ Saxagliptin 2.5-5
mg PO QD
￿ Linagliptin 5 mg
PO QD
Benefits
Reduction in A1C level*[22-24,26,29,36-45] 0.5%-1.5% 0.5%-0.9%
Reduction in fasting plasma glucose*[29,39-41,49-51] ↓7 to 74 mg/dL ↓11 to 29 mg/dL
Reduction in postprandial glucose*[9,27,51,54,55] ↓41 to 47 mg/dL ↓49 to 68 mg/dL
Weight effect [14,22,24,26,29,37,39-41,44,45,49,50,52,60] ↓1-4 kg ↓0.9 to ↑1.4 kg
Effect on triglycerides [24,29,36,37,39,41,49,60,62] ↓12-40 mg/dL ↑16 mg/dL to ↓35
mg/dL
Reduction in systolic blood pressure [13,14,24,29,36,37,39,41,49,60,62] ↓1-7 mm Hg 0 to ↓3.9 mm Hg
May improve markers of pancreatic b-cell function (such as homeostasis model assessment-b-cell
function, fasting insulin, fasting proinsulin to insulin ratio, fasting C-peptide)[8,13,22-24,26,30]
✓✓
Disadvantages
Incidence of mild/moderate hypoglycemia**[9,10,24,26,36-39,41,43-45,52,55,64] 0%-12% 0%-4%
Nausea [13,33-35] 26%-28% 0-1%
Hypersensitivity reactions [33-35] Rare (exenatide) ✓
Antibody formation [31-35,79,80] 30-67% E; 8% L NR
*As monotherapy or as add-on therapy.
**Generally included asymptomatic hypoglycemia or symptomatic hypoglycemia with blood glucose < 55 mg/dL not requiring third-party assistance.
BID, twice daily; NR, not reported; PO, orally; QD, once daily; SC, subcutaneously
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prolong survival of pancreatic b-cells. These observa-
tions have prompted an assessment of the possible ben-
eficial effects of the GLP-1R agonists and DPP-4
inhibitors on b-cell function in humans. While some
trials have demonstrated improvement of surrogate mar-
kers of b-cell function, others have not [8,10,13,22-30].
Further investigation is ongoing.
GLP-1 is secreted by the L-cells of the small intestine
in response to food ingestion, but undergoes rapid enzy-
matic degradation by DPP-4. As a consequence, inject-
able GLP-1R agonists were developed that resist
degradation by DPP-4. Exenatide (for twice-daily admin-
istration) and liraglutide are the GLP-1R agonists that
are currently available int h eU . S .I na d d i t i o n ,o r a l
inhibitors of DPP-4 have been developed that prolong
the action of endogenous GLP-1. Sitagliptin, saxagliptin,
and linagliptin are the three DPP-4 inhibitors currently
available in the U.S. The recommended maintenance
doses in the current prescribing information are: exena-
tide 10 μg twice daily [31]; liraglutide 1.2 or 1.8 mg
once daily [32]; sitagliptin 100 mg once daily [33]; saxa-
gliptin 2.5 or 5 mg once daily [34]; and linagliptin 5 mg
once daily [35].
Findings from Clinical Trials
Incretin-based therapies have been investigated in
numerous clinical trials involving patients with T2DM.
These trials have typically involved patients with some-
what different characteristics at baseline. Results of trials
Figure 1 AACE/ACE diabetes algorithm for diabetes control. Algorithm for the metabolic management of type 2 diabetes. Lifestyle
modification is a component of treatment for all patients. Interventions are stratified based upon the current A1C level and whether the patient
is receiving treatment or is drug naïve. Medication choices are prioritized according to safety, risk of hypoglycemia, efficacy, simplicity,
anticipated degree of patient adherence, and cost of medications. Only combinations of medications approved by the US Food and Drug
Administration that provide complementary mechanisms of action are listed. It is essential to monitor therapy with A1C and self-monitoring of
blood glucose and to adjust or advance therapy frequently (every 2 to 3 months) if the appropriate goal for each patient has not been
achieved. [Reprinted from Endocrine Practice, Volume 15, Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G et al.
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes
mellitus: an algorithm for glycemic control, Pages 540-559, Copyright 2009, with permission from the American Association of Clinical
Endocrinologists.]
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more non-incretin agents are described below to provide
a general understanding of the glycemic and non-glyce-
mic effects of the incretin-based agents. To gain a
greater understanding of differences among incretin-
based therapies, results of head-to-head trials comparing
two incretin-based agents are also provided.
Glycemic Effects
A1C
As a consequence of their physiologic actions to regu-
late glucose homeostasis, the GLP-1R agonists and DPP-
4 inhibitors are effective in lowering blood glucose
levels, with a more robust effect with the GLP-1R ago-
nists (Table 1). When administered as monotherapy or
in combination with metformin or other glucose-lower-
ing therapy, the GLP-1R agonists reduce the A1C level
by 0.5% to 1.5% [29,36-41] and the DPP-4 inhibitors by
0.5% to 0.9% [22-24,26,42-45]. Also, patients previously
treated with diet and exercise alone have been observed
to achieve a greater A1C reduction with liraglutide than
those previously treated with glucose-lowering mono-
therapy (-1.6% vs -0.7%, respectively) [37]. Patients with
ab a s e l i n eA 1 Cl e v e l≥9.0% appear to experience a
greater reduction in A1C with sitagliptin than patients
with a baseline A1C level < 8.0% (-1.5% vs -0.6%,
respectively) [22]. Similar results have been observed
with exenatide [40], liraglutide (baseline A1C ≥10%) [13]
and linagliptin [45].
Prospective head-to-head comparative trials have
demonstrated differences among the incretin therapies
with respect to their efficacy in reducing the A1C level as
add-on therapy. In these trials, patients were those who
had inadequate glycemic control with metformin-based
therapy. In one trial after 26 weeks, exenatide 10 μg twice
daily reduced the A1C by 0.8% compared to 1.1% with lir-
aglutide 1.8 mg once daily (P < 0.0001) [13]. Another 26-
week trial showed that liraglutide 1.2 or 1.8 mg once daily
reduced the A1C by 1.2% and 1.5%, respectively, compared
to 0.9% for sitagliptin 100 mg once daily (P <0 . 0 0 0 1v s
Tier 1: Well-validated core therapies
Tier 2: Less well-
validated therapies
At diagnosis:
Lifestyle
+
Metformin
Lifestyle + Metformin
+
Intensive Insulin
Lifestyle + Metformin
+
Pioglitazone
No Hypoglycemia
Edema/CHF
Bone Loss
Lifestyle + Metformin
+
GLP-1 agonistb
No Hypoglycemia
Weight Loss
Nausea/Vomiting
Lifestyle + Metformin
+
Pioglitazone
+
Sulfonylureaa
Lifestyle + Metformin
+
Basal Insulin
Step 1 Step 2 Step 3
Lifestyle + Metformin
+
Basal Insulin
Lifestyle + Metformin
+
Sulfonylureaa
aSulfonylureas other than glyburide or chlorpropamide
bInsufficient clinical use to be confident regarding safety
CHF, congestive heart failure
Figure 2 ADA/EASD algorithm for the management of patients with type 2 diabetes. Algorithm for the metabolic management of type 2
diabetes. Reinforce lifestyle interventions at every visit and check A1C every 3 months until A1C is < 7% and then at least every 6 months. The
interventions should be changed if A1C is ≥ 7%. [Diabetes Care by American Diabetes Association. Copyright 2009 Reproduced with permission
of American Diabetes Association in the format journal via Copyright Clearance Center]
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reductions from baseline were 1.3% and 1.5% for liraglu-
tide 1.2 and 1.8 mg, respectively, and 0.9% for sitagliptin
(P < 0.0001 vs both liraglutide doses) [46]. A third trial
involved initiation and stabilization of insulin glargine as
add-on therapy. After 4 weeks, exenatide (5 μg twice daily
for 2 weeks, then 10 μg twice daily for 2 weeks) lowered
the A1C 1.8% compared to 1.5% for sitagliptin 100 mg
once daily [47]. A fourth trial showed that after 18 weeks,
sitagliptin 100 mg once daily lowered the A1C 0.6% com-
pared to 0.5% for saxagliptin 5 mg once daily [48].
Fasting plasma glucose
Fasting plasma glucose (FPG) levels are also reduced
when GLP-1R agonists or DPP-4 inhibitors are adminis-
tered as add-on therapy to other glucose-lowering
agents (Table 1). Specifically, reductions in FPG are
observed with the addition of a GLP-1R agonist ranging
from 7 to 74 mg/dL [29,39-41,49]. The head-to-head
comparison of exenatide with liraglutide showed that lir-
aglutide caused a significantly greater reduction of the
FPG than exenatide (29 mg/dL vs 11 mg/dL, respec-
tively; P < 0.0001), while exenatide caused a significantly
greater reduction of the postprandial glucose (PPG)
after breakfast (P <0 . 0 0 0 1 )a n dd i n n e r( P = 0.0005) but
not lunch [13].
As add-on therapy, the FPG is reduced 11 to 29 mg/dL
with the addition of a DPP-4 inhibitor to existing glu-
cose-lowering therapy [48,50,51], with a greater reduc-
tion with sitagliptin compared to saxagliptin (16 mg/dL
vs 11 mg/dL, respectively) [48]. The head-to-head com-
parison of liraglutide with sitagliptin showed that liraglu-
tide reduced the FPG 31 to 37 mg/dL compared to 11
mg/dL for sitagliptin at 1 year (P≤0.0001) [46].
Postprandial glucose
Reduction in the A1C level observed with the GLP-1R
agonists and DPP-4 inhibitors appears to result primar-
ily from the generally greater reduction of the postpran-
dial glucose (PPG) level compared to the FPG level
(Table 1) [23,26,37,45,52]. A GLP-1R agonist appears
preferred if the PPG level is significantly elevated, while
a DPP-4 inhibitor may be preferred if there is modest
elevation of both FPG and PPG [53].
Patients on stable doses of metformin and a sulfony-
lurea who were treated with exenatide 10 μgt w i c ed a i l y
experienced significantly greater reduction in PPG excur-
sions following breakfast and dinner than patients treated
with insulin glargine once daily (P < 0.001) [54]. When
once-daily liraglutide 1.2 mg or 1.8 mg was administered
for 26 weeks as add-on therapy with metformin, the PPG
level was reduced by 41 mg/dL and by 47 mg/dL, respec-
tively, compared with a reduction of 45 mg/dL for glime-
piride 4 mg once daily [55].
Treatment with sitagliptin 100 mg once daily for 18
weeks, when added to metformin, reduced the PPG by
68 mg/dL, compared with a reduction of 14 mg/dL for
placebo [27]. Similarly, when saxagliptin is added to
metformin therapy at doses of 2.5 mg once daily or
5 mg once daily, versus placebo, the PPG is reduced by
62 mg/dL, 58 mg/dL, and 18 mg/dL, respectively [9].
Linagliptin 5 mg once daily has been shown to reduce
the PPG 49 mg/dL over 24 weeks compared to an
increase of 18 mg/dL with placebo [51].
Effects on pancreatic b-cell function
Several clinical trials have examined the effects of the
GLP-1R agonists and DPP-4 inhibitors on pancreatic b-
cell function in persons with T2DM (Table 1). Since
direct measurement of pancreatic b-cell function in
humans is not possible, studies have measured a variety
of surrogate markers. Improvement in some but not all
markers has been observed in most studies involving the
GLP-1R agonists [13,28,30,36,55,56] or DPP-4 inhibitors
[9,50,57,58].
Nonglycemic Effects
The effects of the GLP-1R agonists and DPP-4 inhibitors
on nonglycemic parameters also serve to differentiate
these agents from other glucose-lowering agents.
Body weight
Among the most important nonglycemic differences is the
observation that patients treated with a GLP-1R agonist
experienced a mean weight loss of 1 kg to 4 kg in clinical
trials (Table 1) [29,37,39-41,49,52]. For example, after 3
years of exenatide treatment, 84% of patients lost weight,
with 50% losing at least 5% of baseline body weight [59].
T h ea m o u n to fw e i g h tl o s ti n c r e a s e dw i t hh i g h e rb o d y
mass index [59]. The DPP-4 inhibitors are considered to
be weight neutral; however, some patients experience a
slight increase in weight, others a slight decrease
[14,22,24,26,44,45,50,60]. The difference in weight effect
between the GLP-1R agonists and DPP-4 inhibitors prob-
ably results from the ability of the GLP-1R agonists to
reduce caloric intake by promoting satiety, and possibly by
delaying gastric emptying [17,61]. The DPP-4 inhibitors
do not appear to promote satiety or delay gastric
emptying.
Lipids and blood pressure
While the GLP-1R agonists and DPP-4 inhibitors should
not be used as primary therapy for cardiovascular disease,
improvements in the lipid profile and reductions in blood
pressure may offer additional benefits in an at-risk popu-
lation with T2DM (Table 1). The mechanism for the
lipid-lowering effect of the incretins is unknown, but may
be related to their glucose-lowering effects as observed
with other glucose-lowering agents or effects on free fatty
acid metabolism. The greatest improvement in the lipid
profile is observed in the triglyceride level, which is
reduced by 12 to 40 mg/dL with the GLP-1R agonists
[29,36,37,39,41,49,62], while the change with the DPP-4
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decrease of 35 mg/dL [24,60]. Small changes in the LDL-
cholesterol and HDL-cholesterol levels have been
observed with both the GLP-1R agonists and the DPP-4
inhibitors.
The GLP-1R agonists also have been shown to lower
systolic blood pressure 1 to 7 mm Hg; changes in dia-
stolic blood pressure have been similar to placebo
[13,29,36,37,39,41,49,62]. The mechanism for blood
pressure reduction with the GLP-1R agonists is unclear.
While an association with weight loss cannot be ruled
out, one investigation involving liraglutide found that
the reduction in systolic blood pressure occurred before
substantial weight loss [29]. The effects on blood pres-
sure with the DPP-4 inhibitors are limited [24,51,60].
Safety and Tolerability
The good safety and tolerability of the GLP-1R agonists
and DPP-4 inhibitors are well documented leading the
AACE/ACE guidelines to conclude that the GLP-1R
agonists are safer than sulfonylureas or glinides with
respect to the risk of hypoglycemia [3]. While the guide-
lines also note the risk of gastrointestinal side effects
(which are usually transitory) with the GLP-1R agonists
and excellent tolerability of the DPP-4 inhibitors, some
adverse events encountered in clinical practice bear
discussion.
Hypoglycemia
A low incidence of hypoglycemia is observed with the
GLP-1R agonists and DPP-4 inhibitors, likely because of
their glucose-dependent actions on insulin and glucagon
secretion (Table 1). For this reason, the ADA/EASD con-
sensus statement recommends a GLP-1R agonist when
hypoglycemia is a major concern, such as for those who
h a v eh a z a r d o u sj o b sa n dw e i g h tl o s si sb e n e f i c i a l[ 2 ] .
Furthermore, the US Federal Aviation Administration
includes the GLP-1R agonists and DPP-4 inhibitors in
the list of allowable medications for aviators [63]. Severe
hypoglycemia (generally defined as symptomatic–such as
confusion, blurred vision, sweating–and requiring third-
party assistance) has not been observed in trials of exena-
tide [36,52], liraglutide [37,38], sitagliptin [24,44], saxa-
gliptin [26], or linagliptin [45] as monotherapy. Mild to
moderate hypoglycemia (generally defined as asympto-
matic or symptomatic with a blood glucose < 55 mg/dL
but not requiring third-party assistance) occurs in 4% to
9% of patients receiving monotherapy treatment with
exenatide [36,52], 0% to 12% with liraglutide [37,38], 0%
to 4% with sitagliptin [22-24], 0-6% with saxagliptin [26],
and 0% with linagliptin [45]. A slightly higher incidence
of mild to moderate hypoglycemia is observed when
incretin-based therapy is combined with 1 or more glu-
cose-lowering agents [9,10,39,41,43,55,64]. However,
when combined with a sulfonylurea, mild to moderate
hypoglycemia has been reported by up to 36% of patients
treated with the combination of a GLP-1R agonist or a
DPP-4 inhibitor [14,65], which necessitates reducing the
dose of the sulfonylurea, usually by half.
Nausea and Vomiting
Early experience with the GLP-1R agonists showed that
transient nausea was common. This led to a dose titra-
tion strategy when initiating therapy, which reduced the
incidence of transient nausea to 28% with exenatide and
to 26% with liraglutide in a head-to-head comparison;
vomiting occurred in 10% and 6%, respectively (Table 1)
[13]. Exenatide should be initiated at a dose of 5 μgt w i c e
daily and taken within 60 minutes before the morning
a n de v e n i n gm e a l s ;t h ed o s ec a nb ei n c r e a s e dt o1 0μg
twice daily after 1 month based on clinical response [31].
Liraglutide should be initiated independent of meals at a
dose of 0.6 mg once daily for 1 week and then increased
to 1.2 mg once daily. If the 1.2 mg dose does not result in
acceptable glycemic control, the dose of liraglutide can be
increased to 1.8 mg once daily to achieve glycemic con-
trol [32]. The incidence of nausea with the DPP-4 inhibi-
tors is similar to placebo [22,23,26].
Acute pancreatitis
The possibility of acute pancreatitis, which was first
raised by postmarketing reports with exenatide, led to
changes in monitoring for its occurrence in subsequent
clinical trials with incretin-based agents. These investiga-
tions show that acute pancreatitis has been observed
rarely in patients treated with exenatide [31], liraglutide
[32], and sitagliptin [33], and linagliptin [35]. For exam-
ple, separate pooled analyses show that the number of
cases of pancreatitis per 1000 patient-years was 2.2 for
liraglutide (vs 0.6 for comparators) [32], 1.2 for sitagliptin
(vs 1.0 for comparators) [33], and 1.7 for linagliptin (vs 0
for placebo) [35]. Similar pooled data for exenatide and
saxagliptin are not available. However, establishing exe-
natide, liraglutide, sitagliptin, or linagliptin as the cause
has not been possible because patients with T2DM
regardless of treatment have a nearly 3-fold greater risk
of pancreatitis compared with those without diabetes
[66]. In addition, retrospective analysis of a health insur-
ance database involving nearly 88,000 patients with 1-
year follow-up demonstrated a similar risk of pancreatitis
with exenatide, sitagliptin, metformin, and glyburide [67].
It is, nonetheless, important to educate patients about
risk factors for pancreatitis, eg, gallstones, alcoholism,
high triglycerides, and the immediate steps they should
take if signs and symptoms suggestive of pancreatitis
occur. At present, in patients with a history of pancreati-
tis, exenatide, liraglutide, and sitagliptin should not be
prescribed [31-33], The FDA has required the manufac-
turers of exenatide, liraglutide, sitagliptin, saxagliptin,
and linagliptin to conduct further epidemiologic studies
of pancreatitis to clarify this issue [68-72].
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Hypersensitivity reactions have been observed with each
of the three DPP-4 inhibitors (Table 1). For sitagliptin,
the most serious hypersensitivity reaction is Stevens-
Johnson syndrome, which requires immediate treatment
discontinuation if signs and symptoms of hypersensitiv-
ity occur [33]. Urticaria and facial edema occur in 1% to
2% of patients treated with saxagliptin [34], while urti-
caria, angioedema, localized skin exfoliation, or bron-
chial hyperreactivity can occur with linagliptin [35].
Further investigation of hypersensitivity reactions is
ongoing with saxagliptin [72] and linagliptin [73], as
mandated by the FDA.
Renal failure
Ischemic renal failure has been reported in four patients
within two to nine months of starting exenatide [74].
All four patients presented with nausea, vomiting, or
decreased fluid intake. In one patient, the renal failure
was characterized by ischemic glomeruli with moderate
to severe interstitial fibrosis, tubular atrophy, and early
diabetic nephropathy. Recovery, which was incomplete
in three of the patients upon cessation or dose reduc-
tion, was hypothesized to be due to volume contraction.
Since exenatide, as well as sitagliptin and saxagliptin, are
predominantly eliminated via the kidneys, the dose of
these three agents must be reduced when the creatinine
clearance is less than 50 mL/minute; exenatide is con-
traindicated if the creatinine clearance is less than 30
mL/minute [31,33,34]. Liraglutide and linagliptin do not
require dosage adjustment in renal dysfunction [32,35].
Long-term Outcomes
The GLP-1R agonists and DPP-4 inhibitors have only
become available in recent years, the first being exena-
tide in April 2005; thus, the long-term efficacy and
safety of these 5 agents have not yet been established.
Of the numerous ongoing investigations, several have
been required by the FDA to clarify the long-term safety
of these agents. One investigation relates to exenatide
and a possible association between this agent and the
development of thyroid cancer, based on postmarketing
reports [69]. A second study is a preclinical investigation
with liraglutide to determine the lifetime risk of devel-
oping thyroid C-cell tumors [70]. During review of the
new drug application for liraglutide, the US FDA deter-
m i n e dt h a tt h e r ei sal o wr i s ko ft h y r o i dc a n c e ri n
humans based on changes in rodents at levels of liraglu-
tide many times those anticipated in humans [68].
Other investigation suggests that C-cell hyperplasia in
rats and mice may be mediated by a GLP-1 receptor-
mediated mechanism [75]. GLP-1 receptor expression in
thyroid C-cells in humans and monkeys is low such that
exposure to liraglutide at more than 60 times human
exposure levels for 20 months did not result in C-cell
hyperplasia in monkeys. Further, the level of calcitonin,
a biomarker for medullary thyroid cancer, remained at
the lower end of the normal range in humans exposed
to liraglutide for 2 years. The FDA has required that an
epidemiologic study of thyroid cancer be carried out
with exenatide [69], as well as animal studies and moni-
toring a 15-year cancer registry with liraglutide [70]. In
addition, a boxed warning concerning the current find-
ings of medullary thyroid cancer in animals has been
included in the prescribing information for liraglutide
[32]. An association with sitagliptin [33] or saxagliptin
[34] and thyroid cancer has not been identified.
Clinical trials investigating the cardiovascular effects of
liraglutide [70], saxagliptin [72], and linagliptin [73] are
also required (and are ongoing), since the clinical eva-
luations of these drugs were completed prior to Decem-
ber 2008 when the FDA adopted new standards
regarding cardiovascular safety for all new antidiabetic
drugs. These standards were in response to data sug-
gesting a serious risk of cardiovascular events with some
medications developed for the treatment of T2DM.
Based on available data, the potential for adverse cardio-
vascular events with liraglutide, saxagliptin, and linaglip-
tin cannot yet be definitively excluded.
These ongoing safety evaluations will better define the
long-term safety of the GLP-1R agonists and DPP-4
inhibitors and identify safety issues, if any, earlier than
previous and current postmarketing surveillance.
Cost
In addition to efficacy and safety, cost is an important
issue in selecting treatment and should be discussed
with the patient. The purchase price for therapy with a
GLP-1R agonist or DPP-4 inhibitor at a pharmacy is
greater than for most other glucose-lowering agents.
However, cost can vary substantially depending on for-
mulary status and pharmacy. Also, patient insurance will
affect the out-of-pocket cost to the patient since major
costs are usually covered by insurance with a copay
from the patient that is often dependent on formulary
status. While the cost of a medication to the patient is a
critical consideration in selecting therapy, the impact of
a treatment on other direct and indirect costs also must
be considered. Limited data have shown that the annual
total cost of medical care ($19,293 vs $23,782, respec-
tively; P < 0.0001) and total cost of diabetes-related
medical care ($7,833 vs $8,536, respectively; P < .0001)
with exenatide were significantly lower than with insulin
glargine [76], including a lower cost related to the treat-
ment of hypoglycemia [77]. Similarly, preliminary evi-
dence indicates that liraglutide may reduce the total
cost of diabetes-related care compared to glimepiride
[78]. The analysis included costs due to ocular events
and neuropathy leading to amputation. Although these
data are preliminary, they are consistent with the clinical
Cobble Diabetology & Metabolic Syndrome 2012, 4:8
http://www.dmsjournal.com/content/4/1/8
Page 7 of 10profile of the GLP-1R agonists and DPP-4 inhibitors, as
discussed above.
Conclusion
Following diagnosis of T2DM, glycemic control should
be achieved within 3 to 6 months and maintained using
a treat-to-target approach. Furthermore, treatment fail-
ure must not be accepted and must always be addressed
quickly. Use of the GLP-1R agonists and DPP-4 inhibi-
tors enables the primary care clinician to approach the
management of patients with T2DM in a way that com-
plements other therapies through the actions of these
agents on the incretin pathway. This is especially impor-
tant given that the incretin system is thought to be
responsible for up to 70% of insulin secretion in
response to oral glucose or a meal. Use of the GLP-1R
agonists and DPP-4 inhibitors also enable the clinician
to minimize the risk of some of the complications com-
monly encountered when treating patients with T2DM,
such as hypoglycemia and weight gain. For these rea-
sons, the GLP-1R agonists and DPP-4 inhibitors play an
important role in the treatment of patients with T2DM,
as reflected in recent consensus guidelines. But there are
important differences among the incretin-based agents.
The GLP-1R agonists require subcutaneous administra-
tion, produce pharmacological levels of GLP-1 activity,
promote weight loss, have a more robust glucose-lower-
ing effect, and have a higher incidence of adverse gastro-
intestinal effects. In contrast, DPP-4 inhibitors are taken
orally, increase the half-life of endogenous GLP-1, are
weight neutral, and are more commonly associated with
nasopharyngitis. Although current evidence indicates
these agents are safe and generally well-tolerated, the
results of ongoing intensive safety evaluations will alert
health care practitioners at the earliest possible time to
important safety issues, should they occur.
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